Trial Profile
A Phase 3 study to assess the efficacy and safety of JTZ-951 in ESA naive anemic patients with chronic kidney disease receiving hemodialysis <anemia correction / maintenance study>
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Enarodustat (Primary)
- Indications Anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Japan Tobacco
- 02 Nov 2017 New trial record